

Inhalation Sciences Q2 2023 - EBITDA positive

Redeye provides an update in relation to ISAB's Q2 2023 report. Revenues during the quarter amounted to SEK5.8m (SEK4.2m), 9% higher than our revenue estimate of SEK5.3m, and EBIT came in at SEK-0.1m (SEK-4.0m), better than our expectations of SEK-0.9m. We are positive about yesterday's report as the company was EBITDA positive, and we have chosen to make some minor changes to our OPEX estimates for the rest of 2023. However, this does not render any changes in our fair value range, including a base case of SEK17.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Inhalation Sciences Q2 2023 - EBITDA positive